Ipamorelin + Tesamorelin 2-Vial Kit – 10 mg and 20 mg

Global Peptides Lab presents this Ipamorelin + Tesamorelin kit as a two-vial package containing two separately sealed peptide powders. The package includes one vial of Ipamorelin labelled 10 mg and one vial of Tesamorelin labelled 20 mg. Both materials are supplied in lyophilized form, meaning the powder has been freeze-dried rather than supplied as a prepared liquid.

This is an important distinction: the package contains two individual vials, not one vial containing a premixed peptide blend. Each vial has its own batch identification and reported laboratory results, allowing the accompanying documentation to be reviewed for the relevant material.

The product specifications below provide a clear overview of the supplied format, labelled quantities, packaging, and available test information.

Product Specifications

• Product name: Ipamorelin + Tesamorelin 2-Vial Kit
• Brand: Global Peptides Lab
• Number of vials: 2 separate vials
• Ipamorelin labelled quantity: 10 mg
• Tesamorelin labelled quantity: 20 mg
• Form: Lyophilized powder
• Reconstitution status: Not reconstituted
• Container: Sealed vial with flip-top closure
• Vial size: 3 mL each
• Reported testing: Purity, weight, and endotoxin (LPS)
• Packaging format: Separate containers for each peptide

The 10 mg and 20 mg figures refer to the labelled quantities of the individual materials. They should not be confused with the reported laboratory measurements, which are listed separately below.

Laboratory Testing and Batch Information

Transparent product documentation helps readers understand what has been measured and which batch a result refers to. For this kit, the supplied information includes separate purity results, measured weights, batch identifiers, and an endotoxin screening result.

Ipamorelin test information

The supplied Ipamorelin test data report a purity result of 99.776% and a measured quantity of 11.98 mg.

• Reported purity: 99.776%
• Reported measured weight: 11.98 mg
• Batch number: 08-25-0710G
• Container: Separate sealed 3 mL vial
• Form: Lyophilized powder

Tesamorelin test information

The supplied Tesamorelin test data report a purity result of 99.139% and a measured quantity of 20.94 mg.

• Reported purity: 99.139%
• Reported measured weight: 20.94 mg
• Batch number: 07-25-0420D
• Container: Separate sealed 3 mL vial
• Form: Lyophilized powder

Endotoxin screening

The supplied test information records the endotoxin (LPS) result as Pass. Endotoxin testing assesses a specific category of bacterial components. A passing result should be interpreted according to the test method, acceptance limit, sample, and batch covered by the laboratory report.

An endotoxin result alone does not establish sterility, confirm the absence of every contaminant, or demonstrate that a product is safe for injection. Customers reviewing laboratory documentation should consult the underlying report for the method used, testing laboratory, date, and acceptance criteria.

Understanding the Two Peptides

Ipamorelin and tesamorelin are distinct synthetic peptides investigated in relation to growth-hormone signalling. They are not interchangeable substances, and research concerning one peptide cannot automatically be applied to the other.

Ipamorelin is commonly described in scientific literature as a growth-hormone secretagogue that acts through the ghrelin receptor. Research has examined its biological activity and effects on growth-hormone release. However, available evidence and safety information are limited, and the results of laboratory or clinical investigations do not establish the safety or effectiveness of an unapproved product for general human use.

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It has an approved prescription-drug use in the United States for a specific medical indication involving excess abdominal fat associated with HIV-related lipodystrophy. That approval applies to the authorised medicinal product and its approved indication; it does not mean that every tesamorelin preparation, research material, or combination product is approved for medical use.

The two peptides therefore have different pharmacological profiles and regulatory considerations. The presence of both materials in one package does not establish that combining them produces a particular effect, nor does it establish the safety of using them together. The combination itself should not be described as an approved treatment.

Lyophilized Powder and Packaging

Lyophilization is a freeze-drying process used to remove water from a material under controlled conditions. In peptide products, this process can support the presentation of a dry material, but the actual stability of a particular preparation depends on its composition, manufacturing process, packaging, and storage conditions.

This kit is supplied as dry powder rather than reconstituted liquid. Each peptide is contained in its own sealed vial with a flip-top closure. The stated 3 mL vial size describes the container capacity; it does not mean that either vial contains 3 mL of liquid.

No reconstitution volume, administration instructions, or dosing schedule is specified in the supplied product information. These details should not be inferred from the vial size or labelled mass.

Documentation and Quality Transparency

When reviewing peptide laboratory documentation, it is useful to distinguish between purity, measured weight, identity, sterility, and endotoxin results. These are different quality attributes, and one result cannot substitute for another.

The reported purity percentages describe the values supplied for the two batches. To assess their meaning fully, consult the original certificates of analysis and check the analytical method, reference standard, sample identification, and laboratory details. Similarly, measured weight should be interpreted according to the report’s method and units.

For Global Peptides Lab, keeping the batch identifiers alongside the correct test results helps readers identify which record corresponds to each vial. Where available, batch-specific certificates should be provided without changing the reported values or presenting a supplier-reported result as independently verified when independent verification has not been established.

Research Context and Responsible Use

Peptide research involves specialised analytical methods and careful evaluation of biological activity, material identity, purity, and potential safety concerns. Results obtained from purified laboratory material cannot automatically be extrapolated to a finished medicinal product or to outcomes in humans.

Ipamorelin has recognised evidence gaps and safety concerns, including concerns raised by the US Food and Drug Administration about certain compounded formulations. Tesamorelin’s established prescription use is limited to its authorised indication and does not establish the safety of this particular two-vial package or its combined use with ipamorelin.

This product description is intended to communicate the supplied material specifications and reported test information. The kit should not be represented as an approved treatment, a proven body-composition solution, or a product with established benefits for healthy individuals. Research-use labelling does not by itself establish legal permission to sell or use a substance in every jurisdiction.

Frequently Asked Questions

Is this one blended vial or two separate vials?

It is a two-vial kit. One vial contains the material labelled Ipamorelin 10 mg, and the other contains the material labelled Tesamorelin 20 mg. They are not supplied as a single premixed vial.

What form are the peptides supplied in?

Both materials are supplied as lyophilized powder. They have not been reconstituted into liquid.

What purity results are reported?

The supplied test information reports 99.776% purity for Ipamorelin and 99.139% for Tesamorelin. Refer to the relevant batch-specific laboratory reports for the methods and supporting details.

What are the batch numbers?

The reported Ipamorelin batch is 08-25-0710G. The reported Tesamorelin batch is 07-25-0420D.

What does the endotoxin result mean?

The supplied endotoxin (LPS) result is recorded as Pass. This result relates to the applicable endotoxin test and does not independently establish sterility or overall suitability for human use.

Are the reported weights the same as the labelled quantities?

No. The labelled quantities are 10 mg for Ipamorelin and 20 mg for Tesamorelin. The supplied test information separately reports measured weights of 11.98 mg and 20.94 mg, respectively. Consult the original reports to understand precisely what was measured.

Does the combination have established clinical benefits?

The supplied product specifications and purity results do not establish clinical benefits. The safety and effectiveness of this particular combination have not been demonstrated by the information provided here.

Is the kit intended for self-administration?

The supplied specifications do not establish suitability for self-administration. Do not infer a dose, route, or preparation method from the product name, vial size, or labelled quantity. Any medicinal use requires appropriate professional and regulatory guidance.

Summary

The Ipamorelin + Tesamorelin 2-Vial Kit from Global Peptides Lab comprises two separately sealed vials of lyophilized powder: Ipamorelin labelled 10 mg and Tesamorelin labelled 20 mg. The supplied batch information reports purity values of 99.776% and 99.139%, measured weights of 11.98 mg and 20.94 mg, and an endotoxin screening result of Pass.

The product is supplied unreconstituted in separate 3 mL flip-top vials. Its reported results should be assessed against the corresponding laboratory documentation, and they should not be interpreted as proof of sterility, clinical effectiveness, or suitability for human use.